VACCINEX INC (VCNX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2024, filed Apr 15, 2025. Each column of the statement tables below links to the filing it was taken from.
VACCINEX INC (VCNX) reported $601K in revenue for fiscal year 2024, up 5.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Vaccinex remains a development-stage business: 2024 revenue of $601K sat beside $12.5M of research spending, not commercial scale.
In FY2022, operating cash flow of-$19.1M nearly matched a net loss of$19.8M . Across FY2020-FY2022, that close pairing indicates earnings quality was defined by cash-consuming development activity rather than a large accrual gap.
By FY2024, liabilities of
R&D declined from
Financial Health Signals
VACCINEX INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
VACCINEX INC generated $213K in revenue in Q4 2024. Against the prior quarter it is up 309.6%.
VACCINEX INC earned -$0.03 per diluted share (EPS) in Q4 2024. Against the prior quarter it is up 98.9%.
Not reported for Q4 2024.
Not reported for Q4 2024.
Cash & Balance Sheet
VACCINEX INC recorded an outflow of $3.9M in free cash flow in Q4 2024, representing a cash shortfall after capex. This represents an increase of 49.2% from the same quarter a year earlier. Against the prior quarter it is down 22.3%.
VACCINEX INC held $1.1M in cash against $0 in long-term debt as of Q4 2024, with $5.1M of liabilities due within a year.
Not reported for Q4 2024.
Margins & Returns
None of these metrics is reported for Q4 2024.
Capital Allocation
VACCINEX INC invested $2.1M in research and development in Q4 2024. Against the prior quarter it is down 32.6%.
VACCINEX INC reported no capital expenditure in Q4 2024. Against the prior quarter it is down 100.0%.
Not reported for Q4 2024.
VCNX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $213K | $52K+160.0% | $232K | $104K-81.1% | N/A | $20K-60.0% | N/A | $550K |
| R&D Expenses | $2.1M | $3.2M-27.3% | $3.9M-23.5% | $3.4M-11.3% | N/A | $4.4M+27.0% | $5.0M+31.4% | $3.8M+28.5% |
| SG&A Expenses | $1.5M | $1.4M-4.0% | $2.1M+3.1% | $1.8M+4.1% | N/A | $1.5M+6.1% | $2.0M+30.1% | $1.7M+5.9% |
| Operating Income | N/A | -$4.6M+22.0% | -$5.7M+19.1% | -$5.1M-1.8% | N/A | -$5.8M-21.7% | -$7.1M-31.0% | -$5.0M-8.5% |
| EBITDA | N/A | -$4.5M+22.0% | -$5.7M+19.2% | -$5.0M-1.9% | N/A | -$5.8M-22.8% | -$7.0M-31.8% | -$5.0M-8.8% |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $0-100.0% |
| Income Tax | $0 | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$5.7M-16.7% | -$5.6M+20.2% | -$3.9M+21.5% | N/A | -$4.9M-3.2% | -$7.1M-31.2% | -$5.0M-8.0% |
| EPS (Basic) | -$0.03+99.9% | -$2.83+81.4% | -$3.10+87.4% | -$2.94+85.9% | -$39.40-35718.2% | -$15.25-813.2% | -$24.54-18776.9% | -$20.89-17308.3% |
| EPS (Diluted) | -$0.03 | -$2.83 | -$3.10 | -$2.94 | -$39.40 | -$15.25 | -$24.54 | -$20.89 |
| Diluted Shares (Avg) | N/A | 2M | 2M | 1M | N/A | 322,153 | 287,719 | 237,527 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
VCNX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6M-28.5% | $4.9M+89.8% | $2.4M-23.3% | $7.4M+50.5% | $3.6M-54.5% | $2.6M-70.3% | $3.1M-75.5% | $4.9M-73.0% |
| Current Assets | $2.5M-24.4% | $4.8M+115.6% | $2.2M-17.8% | $7.2M+61.9% | $3.3M-55.2% | $2.2M-72.5% | $2.7M-78.2% | $4.4M-75.1% |
| Cash & Equivalents | $1.1M-27.9% | $2.9M+2188.2% | $233K-87.8% | $3.0M-10.6% | $1.5M-76.0% | $127K-98.2% | $1.9M-83.3% | $3.3M-80.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $838K-12.8% | $985K+5.6% | $1.0M+9400.0% | $2.8M | $961K+449.1% | $933K+1766.0% | $11K | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.1M-14.4% | $6.2M-3.9% | $5.2M+49.1% | $4.7M+88.9% | $5.9M+113.4% | $6.4M+180.2% | $3.5M+115.3% | $2.5M+29.1% |
| Current Liabilities | $5.1M-14.1% | $6.2M-2.9% | $5.2M+54.6% | $4.7M+103.7% | $5.9M+133.2% | $6.4M+220.2% | $3.4M+126.9% | $2.3M+30.0% |
| Non-Current Liabilities | $0-100.0% | $0-100.0% | $0-100.0% | $6K-96.8% | $26K-89.5% | $65K-78.8% | $125K-9.4% | $185K+18.6% |
| Long-Term Debt | $0-100.0% | N/A | N/A | $6K-92.7% | $26K-74.3% | $44K-63.0% | $63K-54.3% | $82K-47.4% |
| Total Equity | -$2.5M-7.7% | -$1.3M+65.9% | -$2.9M-577.1% | $2.7M+10.6% | -$2.3M-144.5% | -$3.9M-161.2% | -$423K-103.9% | $2.4M-85.2% |
| Retained Earnings | -$358.6M-5.5% | -$355.2M-5.5% | -$349.5M-5.4% | -$343.8M-5.9% | -$339.9M-6.3% | -$336.6M-7.0% | -$331.7M-7.1% | -$324.6M-6.6% |
Not reported in any period shown, so not listed: Inventory, Goodwill.
VCNX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M+49.2% | -$3.2M-3.6% | -$4.4M+19.8% | -$4.6M+8.1% | -$7.7M-68.2% | -$3.1M+25.3% | -$5.5M-3.3% | -$5.0M-0.9% |
| Depreciation & Amortization | $17K-35.8% | $24K-22.6% | $25K-16.7% | $27K-12.9% | $27K-41.1% | $31K-53.7% | $30K-44.4% | $31K-24.4% |
| Stock-Based Compensation | N/A | $76K-33.9% | $112K-11.1% | $96K-25.6% | N/A | $115K-14.2% | $126K-8.7% | $129K-8.5% |
| Capital Expenditures | $0 | $8K-55.6% | $14K | $0-100.0% | $0-100.0% | $18K-63.3% | $0 | $49K |
| Free Cash Flow | -$3.9M+49.2% | -$3.2M-3.3% | -$4.4M+19.6% | -$4.6M+9.0% | -$7.7M-68.2% | -$3.1M+25.8% | -$5.5M | -$5.1M |
| Investing Cash Flow | $0 | -$8K+55.6% | -$14K | $0+100.0% | $0-100.0% | -$18K+63.3% | $0 | -$49K |
| Financing Cash Flow | $2.1M-76.7% | $5.9M+342.0% | $1.7M-58.7% | $6.1M+200.3% | $9.1M+140.5% | $1.3M+7110.5% | $4.1M+22833.3% | $2.0M-84.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VCNX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -8753.9% | -2466.4% | -4878.9% | N/A | -29170.0% | N/A | -906.5% |
| Net Margin | N/A | -11023.1% | -2427.2% | -3747.1% | N/A | -24560.0% | N/A | -902.2% |
| Return on Equity | N/A | N/A | N/A | -146.8%+60.0pp | N/A | N/A | N/A | -206.8%-178.4pp |
| Return on Assets | N/A | -118.1%+73.9pp | -237.9%-9.1pp | -52.9%+48.5pp | N/A | -192.0%-136.8pp | -228.8%-186.0pp | -101.4%-76.0pp |
| Current Ratio | 0.50-0.1x | 0.77+0.4x | 0.42-0.4x | 1.52-0.4x | 0.57-2.4x | 0.35-3.7x | 0.79-7.4x | 1.91-8.1x |
| Debt-to-Equity | N/A | N/A | N/A | 0.000.0x | N/A | N/A | N/A | 0.030.0x |
| Asset Turnover | 0.08 | 0.010.0x | 0.10 | 0.01-0.1x | N/A | 0.010.0x | N/A | 0.11 |
| FCF Margin | -1846.0% | -6182.7% | -1909.0% | -4453.9% | N/A | -15565.0% | N/A | -925.3% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| VACCINEX INC VCNX | FY2024 | $601K | N/A | N/A | $2.7M | — |
| AXIM BIOTECHNOLOGIES INC AXIM | FY2023 | $40K | -$8.1M | N/A | $1.7M | — |
| GALERA THERAPEUTICS INC GRTX | FY2025 | N/A | N/A | N/A | $6.5M | — |
| OCEAN BIOMEDICAL INC OCEA | FY2024 | N/A | N/A | N/A | $6.8M | — |
| AYALA PHARMACEUTICALS INC ADXS | FY2023 | $13K | -$48.1M | N/A | $25.7M | — |
Where VACCINEX INC Ranks
Frequently Asked Questions
What is VACCINEX INC's annual revenue?
VACCINEX INC (VCNX) reported $601K in total revenue for fiscal year 2024. This represents a 5.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is VACCINEX INC's revenue growing?
VACCINEX INC (VCNX) revenue grew by 5.4% year-over-year, from $570K to $601K in fiscal year 2024.
How much debt does VACCINEX INC have?
As of fiscal year 2024, VACCINEX INC (VCNX) had $1.1M in cash and equivalents against $0 in long-term debt.
What are VACCINEX INC's total assets?
VACCINEX INC (VCNX) had $2.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are VACCINEX INC's capital expenditures?
VACCINEX INC (VCNX) invested $22K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does VACCINEX INC spend on research and development?
VACCINEX INC (VCNX) invested $12.5M in research and development during fiscal year 2024.
What is VACCINEX INC's current ratio?
VACCINEX INC (VCNX) had a current ratio of 0.50 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is VACCINEX INC's P/E ratio?
VACCINEX INC (VCNX) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $2.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is VACCINEX INC's price-to-sales ratio?
VACCINEX INC (VCNX) trades at 4.5x sales, its market capitalization divided by revenue of $601K revenue, FY2024. The market capitalization is $2.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is VACCINEX INC's debt-to-equity ratio negative or not reported?
VACCINEX INC (VCNX) has negative shareholder equity of -$2.5M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.